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Localization of clusterin in the epimembranous deposits of 
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Localization of c1usterin in the epimembranous deposits of passive 
Heymann nephritis. The membrane attack complex of complement 
(MAC) plays an important role in the mediation of proteinuria in 
experimental membranous nephropathy induced by Heymann antise-
rum. SP-40,40 is a recently described serum protein which appears to 
inhibit the formation of cytolytic MAC in a manner analogous to S 
protein/vitronectin. SP-40,40 is homologous to proteins originally iso-
lated from rat and ram seminal fluid (sulfated glycoprotein 2 and 
clusterin, respectively). By current convention, these proteins are 
considered clusterin homologues. The objective of this study was to 
examine the participation of rat clusterin in passive Heymann nephritis. 
Using an antibody to rat clusterin as an immunofluorescent probe, 
clusterin deposits were demonstrated along the glomerular capillary 
wall in an identical pattern to rat C3 and C5b-9. Decomplementation 
using cobra venom factor prevented proteinuria and intraglomerular 
MAC formation. The epimembranous clusterin were not detected in the 
complement-depleted animals. The role of clusterin in the mediation of 
glomerular injury remains unknown, but it is probably related to in situ 
formation of the terminal complement cascade where it may play a 
regulatory role. 
The membrane attack complex (MAC) of complement par-
ticipates in the mediation of certain types of glomerular injury. 
Its role has been most convincingly demonstrated in the exper-
imental model of passive Heymann nephritis (PHN) [1-6]. 
Immunofluorescence studies of human renal biopsies have also 
confirmed the presence of MAC both in association with 
glomerular immune deposits and in regions of glomerular scle-
rosis [reviewed in 2]. 
The MAC consists of the terminal complement components 
C5b, C6, C7, C8, and C9 and it may be generated in one of two 
ways [7]. The C5b-7 complex, which is amphiphilic, may insert 
into the lipid bilayer of the cell membrane, followed by the 
addition of C8 and multiple C9 molecules to form the cytolyti-
cally active C5b-9(m). Alternatively, S protein/vitronectin may 
bind to C5b-7 resulting in the formation of a hydrophilic, 
nonlytic SC5b-9 complex which remains in the fluid phase. S 
protein/vitronectin thus plays an important role as an inhibitor 
of C5b-9(m) formation and may function in vivo to regulate 
end-organ injury. 
Recently another protein was identified within the human 
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SC5b-9 complex and shown to be an inhibitor of the hemolytic 
activity of complement in vitro. SP-40,40 [8, 9], or complement 
cytolysis inhibitor (CLI) [10], is a serum alpha-globulin of 80 kD 
molecular mass which consists of two distinct, disulfide-linked, 
polypeptide chains each of 40 kD. The entire molecule is the 
product of a single gene [9]. This original work by Murphy and 
his colleagues [8, 9] has been confirmed by others [10]. Based 
on amino acid sequence analysis, the rat homologue is sulfated 
glycoprotein 2 (SGP-2) [11]. Rat SGP-2 in turn has high homol-
ogy with ram clusterin [12, 13]. SGP-2 was first identified in the 
supernatant of primary cultures of rat Sertoli cells [14], and 
clusterin was first identified in ram rete testis fluid [15] from 
which it was isolated [16]. These reproductive tract proteins are 
also present in plasma. The role of clusterin in the complement 
cascade has been inferred by homology but has not yet been 
proven in vivo [9, 17]. Still under active investigation, this 
group of homologous proteins, referred to hereafter as clusterin 
by recent concensus [17], may inhibit the cytolytic activity of 
MAC by binding to C5b6 [8, 9, 18], or by combining with the 
nascent C5b-7 complex [10, 19], to inhibit the insertion of C5b-7 
into cell membranes. Although the biological role of clusterin in 
vivo is unknown, the demonstration of SP-40,40 in human renal 
biopsies in a pattern similar to MAC and S protein [8, 20], lends 
to speculation that it may play an important regulatory role. 
The purpose of this study was to examine the participation of 
clusterin in a MAC-dependent experimental model of glomeru-
lar injury, PHN. 
Methods 
Animals 
Female Lewis rats weighing 100 to 120 g were purchased 
from Charles River Breeding Laboratories (Wilmington, Mas-
sachussetts, USA). They were fed standard rat chow and given 
free access to water. 
Induction of passive Heymann nephritis 
PHN was induced with sheep immune serum raised against 
rat brush border antigens (Heymann antiserum, provided by 
Dr. B. Noble, State University of New York at Buffalo, 
Buffalo, New York, USA) [21]. Each animal was given a single 
intraperitoneal injection of 11.1 mg sheep IgGIlOO g body 
weight. On day 6, the rats were housed individually in meta-
bolic cages to obtain 24-hour collections of urine. Urinary 
albumin excretion rates were quantitated by radial immunodif-
fusion, as described in a previous study [22]. The animals were 
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Fig. 1. Immunofluorescence photomicrographs illustrating the glomerular deposition of sheep anti-rat brush border antibody (IgG). The pattern 
and intensity of straining was similar in complement-sufficient (A) and decomplemented animals (B) 7 days after administration of the antiserum 
(A x 505; B x 570). 
sacrificed on day 7 by complete exsanguination under general 
anaesthesia with enflurane and nitrous oxide. The kidneys were 
harvested immediately. Pieces of renal cortex were snap-frozen 
in 2-methylbutane, precooled in liquid nitrogen and stored at 
-70°C. 
Decomplementation 
One group of rats (N = 6) was depleted of complement using 
cobra venom factor (Cordis Laboratories, Miami, Florida, 
USA). Complement depletion was induced the day prior to the 
administration of Heymann antiserum by the i.p. injection of 
CVF (300 Ulkg) in three equal doses over 24 hours. Comple-
ment depletion was maintained by single daily doses of CVF, 
125 Ulkg on days 0, 1, 2 and 150 U/kg on days 3 to 6. Results 
were compared to a group of complement-replete rats (N = 5). 
Complement depletion was verified by completely negative 
staining of glomeruli for rat C3 and by a 81 to 91% reduction in 
serum total hemolytic complement (CH50) levels compared to 
levels obtained using pooled normal rat serum. The effect of 
decomplementation on the renal distribution of clusterin in 
normal rats was evaluated using the same CVF protocol. The 
kidneys of normal rats were examined following 24 hours (N = 
2) and 3 days (N = 2) of complement depletion. CH50 levels in 
this group of rats were reduced by 97 to 99% of baseline values 
measured prior to CVF administration. The CH50 assay was 
performed according to the method of Kabat and Mayer [23]. 
For this assay, sheep erythrocytes were obtained from Wood-
lyn Laboratories, Guelph, Ontario, Canada, and rabbit anti-
sheep hemolysin from Gibco Laboratories , Burlington, On-
tario, Canada. 
Immunofluorescence studies 
Sections of renal cortex (3 ,.,. thick) were acetone-fixed and 
stained with fluorescein isothiocyanate (FITC)-conjugated goat 
anti-rat C3, and FITC-conjugated rabbit anti-sheep IgG (Orga-
non Teknika, Cappel Division, West Chester, Pennsylvania, 
USA). By indirect immunofluorescence, sections were stained 
for rat C5b-9 using a murine monoclonal anti-rat C5b-9 antibody 
[24] (provided by Dr W. Couser, University of Washington, 
Seattle, Washington, USA), followed by FITC-conjugated goat 
anti-mouse IgG F(ab'h (Tago, Inc., Burlingham, California, 
USA) . Deposition of rat c1usterin was assessed by indirect 
immunofluorescence staining using a rabbit antiserum (provid-
ed by Dr. M. Griswold, Washington State University, Pullman, 
Washington, USA) which was originally published as anti-rat 
dimeric acidic glycoprotein (DAG-protein) antibody [25], fol-
lowed by FITC-conjugated goat anti-rabbit IgG (Organon 
Teknika). DAG-protein was initially isolated from primary 
cultures of rat Sertoli cells and has been renamed sulfated 
glycoprotein 2 (SGP-2) [11]. It is the rat homologue of clusterin 
[12, 13]. The specificity of anti-DAG antiserum was demon-
strated in the original publication [25] both by immunoprecipi-
tation and Western blot analysis using supernatants of cultured 
rat Sertoli cells. Specific reactivity with the two polypeptide 
monomers of DAG was demonstrated. The original paper also 
reported a minor cross reactivity with Band 4 protein, but this 
minor band was subsequently shown to be due to reactivity 
with the precursor SGP-2 molecule and not Band 4 protein [11]. 
The FITC-conjugated antisera used in the indirect immunoflu-
orescence studies were preabsorbed with normal rat plasma and 
shown to be non-reactive with control kidney sections. 
Results 
Decomplementation prevented the development of albumin-
uria following the injection of Heymann antiserum. The mean 
urinary albumin excretion rate on day 6 was 58.5 ± 18.1 mg/loo 
g body weight for the animals with an intact complement 
cascade compared to a mean of 0.8 ± 0.3 mg/tOO g body weight 
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Fig. 2. Immunofluorescence photomicrographs illustrating the glomerular deposition of complement proteins in animals with passive Heymann 
nephritis (day 7). In normal animals, bright granular deposits of rat C3 (A) and rat C5b-9 (C) were present along the glomerular capillary wall. CVF 
treatment depleted serum complement and completely inhibited the glomerular deposition of C3 (B) and activation of the terminal complement 
cascade, C5b-9 (D) (A x 500; B x 495; C x 525; D x 490). 
in the CVF-treated animals (P < 0.001, Student's (-test for 
independent means). 
The pattern and intensity of glomerular staining for sheep IgG 
was similar in both groups (Fig. O. There were diffuse granular 
deposits (3 to 4 + intensity) along the glomerular capillary walls. 
In the complement-sufficient animals, rat C3 and rat C5b-9 were 
present in a similar pattern (3+ intensity) (Fig. 2). In the 
CVF-treated animals, glomerular staining for rat C3 and rat 
C5b-9 was completely negative (Fig. 2). In normal rats, clus-
terin was present in a faint linear pattern along the epithelial 
aspect of the glomerular capillary wall reflecting focally into 
mesangial regions (Fig. 3). This pattern was also observed in 
normal rats depleted of complement by CVF. Focal discontin-
uous deposits were also present along some tubular basement 
membranes, Bowman's capsule and the adventitia of arterioles. 
This pattern was preserved in both experimental groups, al-
though the intensity of staining was significantly reduced in the 
CVF-treated group. In the experimental animals with an intact 
complement cascade, clusterin was also present in a granular 
pattern (1 to 2+ intensity) along the glomerular basement 
membrane, similar in distribution to the sheep IgG, rat C3 and 
rat C5b-9. The pattern of staining for clusterin in the CVF-
250 Clusterin deposits in membranous nephropathy 
Fig. 3. Immunofluorescence photomicrographs illustrating the presence of rat clusterin in passive Heymann nephritis, using anti-SGP-2 
antiserum. In normal rats (A), faint linear deposits of clusterin are present predominantly along the epithelial aspect of the glomerular capillary wall 
reflecting into mesangial regions and in a discontinuous pattern along some tubular basement membranes, Bowman's capsule, and the adventitia 
of arterioles. In rats with PHN (day 7) (B), clusterin is also present in the epimembranous immune deposits. Complement-depletion with CVF 
prevented the interaction of clusterin with the glomerular immune deposits (C) (A ,24 x 250; B x 320; C x 370). 
treated rats was similar to normal rats. No granular deposits 
were present. 
Discussion 
Clusterin is present in the epimembranous immune deposits 
of experimental membranous nephropathy in association with 
rat C5b-9. As a result of systemic complement depletion, MAC 
formation is prevented and deposits of clusterin are no longer 
present. The demonstration of clusterin in association with 
subepithelial immune deposits in rat kidney raises several 
interesting questions about the mechanism of MAC formation 
within the glomerulus. Similar issues were discussed following 
the identification of S protein in this location [26-29] and more 
recently by the 'identification of SP-40,40 in the SC5b-9 compo-
nents both in glomerular immune complexes and in areas of 
glomerulosclerosis in human renal biopsies [20]. It is unlikely 
that these proteins are deposited by entrapment of SC5b-9/ 
clusterin complexes preformed in the circulation since the 
complex is extremely large and unable to migrate across the 
glomerular capillary wall [7, 24]. Left with the option that the 
terminal complement cascade is activated in situ within injured 
glomeruli, the presence of clusterin suggests that it may be 
functioning locally as a regulator of cytolytic MAC formation. 
The actual mechanism by which MAC induces proteinuria 
has not been delineated. Although ultrastructural studies dem-
onstrate the association of MAC with extracellular immune 
deposits, MAC has also been identified along membranous 
structures within the mesangium suggestive of cellular debris 
[5, 30]. In vitro studies demonstrate that Heymann nephritis-
inducing antibodies require complement to induce a cytopathic 
effect on glomerular epithelial cells [31, 32]. Furthermore, 
C5b-9 can directly activate cultured glomerular epithelial [33-
35] and mesangial cells [36, 37]. Thus it remains unclear 
whether all of the MAC present in the subepithelial immune 
deposits was initially inserted into the cell membrane or 
whether other mechanisms enable the biologically active C5b-
9(m) to interact with the immune complexes following cellular 
shedding. Although SC5b-9 has no known pathogenic function, 
it is still possible that its association with the extracellular 
immune deposits may not be biologically inert in the kidney 
[38]. The role of clusterin in the generation of the terminal 
complement complex in situ is unknown. Based on results from 
in vitro studies, the predominant role of clusterin may be an 
inhibitory one through the formation of the cytolytically inac-
tive SC5b-9/clusterin complex. However, just as vitronectin 
may interact with the biologically active C5b-9(m) during com-
plex formation [39], clusterin appears to do the same thing [20]. 
Clusterin and S protein/vitronectin seem to be functionally 
similar proteins. In addition to participating in the formation of 
an inactive terminal complement complex, both are involved in 
cellular adhesion. Vitronectin contains the Arg-Gly-Asp(RGD) 
adhesion sequence and its receptor is a member of the integrin 
family of membrane receptors involved in cell-cell and cell-
matrix interactions [40]. Ram clusterin induces aggregation of 
several cell types [15, 41] and human clusterin also elicits 
aggregation of erythrocytes [17]. The clusterin receptor in-
volved in these cellular interactions has not yet been identified. 
Both clusterin and vitronectin are anionic alpha globulins of 
approximately 80 kD molecular mass. However, they are 
immunologically and structurally distinct [8-10]. Unlike clus-
terin, which is a disulfide-linked heterodimer, vitronectin is a 
single polypeptide chain. Amino acid sequence analysis dem-
onstrates that they are different proteins. The role of clusterin 
as an adhesion-promoting molecule may also be important in 
the genesis of renal injury. However, our study suggests that 
interaction with the terminal complement cascade is necessary 
for its recruitment to the site of immune complex formation. 
Finally, it appears that the family of clusterin-related glyco-
proteins may be larger than initially appreciated. Glycoprotein 
III isolated from bovine adrenal chromaffin granules shows a 
72% level of identity with human SP-40,40 and its encoding 
RNA is also expressed in other organs including the kidney 
[42]. Glycoprotein III has no cell-aggregating activity, but it is 
present in both a soluble and membrane-bound form in chro-
maffin granules and is released in response to acetylcholine. 
The present study demonstrates the presence of clusterin in 
the subepithelial immune deposits of PHN during the process of 
in situ complement activation. The role of clusterin in the 
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mediation of renal injury remains unknown but we speculate 
that it is likely to have an important function. 
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